Compare APT & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APT | CLNN |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.3M | 57.4M |
| IPO Year | 1997 | 2021 |
| Metric | APT | CLNN |
|---|---|---|
| Price | $5.11 | $4.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.20 |
| AVG Volume (30 Days) | 20.4K | ★ 128.9K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $59,142,000.00 | $200,000.00 |
| Revenue This Year | N/A | $24.70 |
| Revenue Next Year | N/A | $9,228.71 |
| P/E Ratio | $21.75 | ★ N/A |
| Revenue Growth | ★ 2.25 | N/A |
| 52 Week Low | $4.34 | $3.25 |
| 52 Week High | $7.50 | $13.50 |
| Indicator | APT | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 47.29 |
| Support Level | $4.86 | $3.92 |
| Resistance Level | $5.45 | $4.70 |
| Average True Range (ATR) | 0.14 | 0.38 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 32.56 | 58.62 |
Alpha Pro Tech Ltd is in the business of protecting people, products, and environments. It is developing, manufacturing, and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical, and dental markets. It also manufactures a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply, consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment, and synthetic roof underlayment accessories.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.